Breast Cancer: Basic and Clinical Research

Superior Efficacy and Safety of a Nonemulsive Variant of the NGcGM3/VSSP Vaccine in Advanced Breast Cancer Patients

Submit a Paper

Breast Cancer: Basic and Clinical Research 2016:10 5-11

Original Research

Published on 18 Feb 2016

DOI: 10.4137/BCBCR.S32785

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Breast Cancer: Basic and Clinical Research


NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vaccine, consisting in very small-sized proteoliposomes (VSSP) obtained by the incorporation of NGcGM3 into the outer membrane protein complex of Neisseria meningitidis, has been previously tested in a Phase II trial in patients with metastatic breast cancer (MBC) but emulsified with Montanide ISA 51. An Expanded Access study was carried out in MBC patients aiming to find if a nonemulsive formulation of NGcGM3/VSSP, without Montanide ISA 51, could be more safe and effective. A total of 104 patients were vaccinated with the nonemulsive formulation (900 μg), subcutaneously (SC), or with the emulsive formulation (200 μg), intramuscularly (IM). An intent-to-treat analysis of efficacy was performed with all patients, and 93 patients were split off according to the site of metastases (visceral/nonvisceral). Of note, SC-treated patients exhibited a superior median overall survival (OS) than IM-treated patients (23.6 vs. 8.2 months; log rank P = 0.001). Even though in the subset of patients with nonvisceral metastases SC vaccination duplicated the median OS compared to the alternative option (31.6 vs. 16.5 months), this difference did not reach statistical significance (log rank P = 0.118). Curiously, in patients with visceral metastases, the advantage of the nonemulsive formulation was more apparent (median OS 21.0 vs. 6.2 months; log rank P = 0.005). The vaccine was safe for both formulations.




BibTex citation   (BIBDESK, LATEX)


What Your Colleagues Say About Breast Cancer: Basic and Clinical Research
The submission process for manuscript publication in Breast Cancer: Basic and Clinical Research is as easy as A,B,C!  Any minor hiccups I encountered were quickly addressed by Libertas' expert staff via prompt emails, and the timelines between initial submission and publication are surely the shortest on record!  I will definitely be submitting future manuscripts to this journal, and look forward to working with their professional and expert team.
Dr Maggie Laidlaw (Nutrasource Diagnostics Inc, Guelph, Ontario, Canada)
More Testimonials

Quick Links

New article and journal news notification services